Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Status:
Completed
Trial end date:
2020-07-02
Target enrollment:
Participant gender:
Summary
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial
to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and
non-alcoholic fatty liver diseases